AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 101 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $188,686 | -37.3% | 18,319 | +0.4% | 0.00% | – |
| Q2 2023 | $300,760 | +79.9% | 18,250 | 0.0% | 0.00% | – |
| Q1 2023 | $167,170 | +27.9% | 18,250 | 0.0% | 0.00% | – |
| Q4 2022 | $130,670 | +1206.7% | 18,250 | +808.0% | 0.00% | – |
| Q3 2022 | $10,000 | +233.3% | 2,010 | +518.5% | 0.00% | – |
| Q4 2021 | $3,000 | +200.0% | 325 | -10.7% | 0.00% | – |
| Q3 2019 | $1,000 | -94.4% | 364 | -97.1% | 0.00% | – |
| Q1 2019 | $18,000 | -43.8% | 12,500 | 0.0% | 0.00% | – |
| Q4 2018 | $32,000 | -41.8% | 12,500 | 0.0% | 0.00% | – |
| Q3 2018 | $55,000 | -28.6% | 12,500 | 0.0% | 0.00% | – |
| Q2 2018 | $77,000 | -15.4% | 12,500 | 0.0% | 0.00% | – |
| Q1 2018 | $91,000 | -11.7% | 12,500 | 0.0% | 0.00% | – |
| Q4 2017 | $103,000 | -21.4% | 12,500 | 0.0% | 0.00% | – |
| Q3 2017 | $131,000 | -5.1% | 12,500 | 0.0% | 0.00% | – |
| Q2 2017 | $138,000 | +14.0% | 12,500 | 0.0% | 0.00% | – |
| Q1 2017 | $121,000 | – | 12,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |